Open Access

miR‑187‑3p increases gemcitabine sensitivity in breast cancer cells by targeting FGF9 expression

  • Authors:
    • Yingqi Wu
    • Li Tao
    • Junwei Liang
    • Yashun Qiao
    • Weiwei Liu
    • Haina Yu
    • Xinghui Yu
    • Lanfang Liu
  • View Affiliations

  • Published online on: May 19, 2020     https://doi.org/10.3892/etm.2020.8770
  • Pages: 952-960
  • Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Breast cancer is the most common type of malignancy in women, which remains a significant health concern worldwide. Gemcitabine is a frequently applied anticancer pharmacological agent. However, the efficacy of gemcitabine is limited by chemoresistance. In the present study, a combination of reverse transcription quantitative‑PCR, cell viability, flow cytometry, luciferase reporter assay and western blot analysis were performed to elucidate the potential effects of miR‑187‑3p on gemcitabine sensitivity in the breast cancer cell line, MDA‑MB‑231. The results revealed that miR‑187‑3p was significantly decreased in the breast cancer tumor tissues. Moreover, the overexpression of miR‑187‑3p significantly inhibited cell viability and promoted apoptosis in MDA‑MB‑231 cells. In addition, miR‑187‑3p overexpression enhanced the anti‑proliferative and pro‑apoptotic effects of gemcitabine, indicating that miR‑187‑3p regulated gemcitabine sensitivity in breast cancer cells. Mechanistically, miR‑187‑3p negatively regulated the expression of fibroblast growth factor 9 (FGF9) by binding to its 3'‑untranslated region. Overexpression of FGF9 reversed the aforementioned effects of miR‑187‑3p overexpression on cell viability and apoptosis in the presence of gemcitabine. In conclusion, the present study indicated that miR‑187‑3p increased gemcitabine sensitivity in breast cancer cells by targeting FGF9 expression.

Related Articles

Journal Cover

August-2020
Volume 20 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Wu, Y., Tao, L., Liang, J., Qiao, Y., Liu, W., Yu, H. ... Liu, L. (2020). miR‑187‑3p increases gemcitabine sensitivity in breast cancer cells by targeting FGF9 expression. Experimental and Therapeutic Medicine, 20, 952-960. https://doi.org/10.3892/etm.2020.8770
MLA
Wu, Y., Tao, L., Liang, J., Qiao, Y., Liu, W., Yu, H., Yu, X., Liu, L."miR‑187‑3p increases gemcitabine sensitivity in breast cancer cells by targeting FGF9 expression". Experimental and Therapeutic Medicine 20.2 (2020): 952-960.
Chicago
Wu, Y., Tao, L., Liang, J., Qiao, Y., Liu, W., Yu, H., Yu, X., Liu, L."miR‑187‑3p increases gemcitabine sensitivity in breast cancer cells by targeting FGF9 expression". Experimental and Therapeutic Medicine 20, no. 2 (2020): 952-960. https://doi.org/10.3892/etm.2020.8770